Drugs / Pegilodecakin
Pegilodecakin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04194892 | Jan → Mar 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03381547 | Dec 2017 → Feb 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03267732 | Sep → Oct 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02009449 | Nov 2013 → Feb 2019 | breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma +3 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT03382912 | Mar 2018 → Aug 2019 | non-small cell lung carcinoma | Eli Lilly and Company | Terminated | Missed primary |
| Phase 2 | NCT03382899 | Mar 2018 → Dec 2019 | non-small cell lung carcinoma | Eli Lilly and Company | Terminated | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02923921 | Mar 2017 → Sep 2019 | malignant pancreatic neoplasm | Eli Lilly and Company | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT03554434 | — | breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma +3 | Eli Lilly and Company | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-16 | Eli Lilly and Company | Results Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival lilly.com ↗
The SEQUOIA trial did not meet its primary endpoint of overall survival. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-10-16 | Eli Lilly and Company | Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival lilly.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegilodecakin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03382912 ↗ |
| Known as | AM0010 | “Participants received AM0010 (pegilodecakin) subcutaneous (SQ) doses of 0.8 mg at 4 mg/mL administered as 0.2 mL injections for body weight ≤80 kg” NCT03381547 ↗ |
| Known as | LY3500518 | “A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)” NCT03381547 ↗ |
| Known as | PEG | “PURPOSE: SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin...” PMID 33555926 ↗ Feb 2021 |
| Known as | Pegilodecakina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989992 ↗ |
| Known as | Pegilodecakine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989992 ↗ |
| Known as | pegylated IL-10 | “nivolumab and PEGylated IL-10 (Pegilodecakin, ARMO BioSciences/Eli Lilly and Company, IN, USA).” PMID 32808556 ↗ Aug 20201“Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist” PMID 31563517 ↗ Sep 2019 |
| Action | Activate | “Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist” PMID 31563517 ↗ Sep 2019 |
| Modality | Protein / enzyme biologic | “PEGylated recombinant human Interleukin-10” NCT02009449 ↗ |
| Route | Subcutaneous | “dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy” NCT02009449 ↗ |